Evolution of clinical and pharmacological parameters after switching from intra-venous to subcutaneous infliximab in patients with inflammatory bowel disease: the REMSWITCH study

A. Buisson (1) , M. Nachury (2) , M. Reymond (3) , Clara Yzet (4, 5) , P. Wils (6) , L. Payen (7) , L. Manlay (1) , B. Pereira (1) , Mathurin Fumery (4, 8)

1 CHU Clermont-Ferrand
2 Hôpital Claude Huriez [Lille]
3 IJPB - Institut Jean-Pierre Bourgin
4 CHU Amiens-Picardie
5 SSPC - Simplification des soins chez les patients complexes - UR UPJV 7518
6 CHRU Lille - Centre Hospitalier Régional Universitaire [CHU Lille]
7 UNICANCER/CRCL - Centre de Recherche en Cancérologie de Lyon
8 PERITOX - Périnatalité et Risques Toxiques - UMR INERIS_I 1

Domaines: Sciences du Vivant [q-bio]

A. Buisson, M. Nachury, M. Reymond, Clara Yzet, P. Wils, et al.. Evolution of clinical and pharmacological parameters after switching from intra-venous to subcutaneous infliximab in patients with inflammatory bowel disease: the REMSWITCH study. Journal of Crohn's and Colitis, 2022, 16 (1), pp.I393-I394. ⟨hal-03665861⟩